Vaccine maker posts a profit and, separately, a $3 billion convertible
Moderna reported third-quarter revenue of $1.313 billion on Friday, up 29% from $1.016 billion a year earlier, and net income of $162 million, compared with a loss of $200 million in the same quarter of 2025, according to its press release filed with the Securities and Exchange Commission. Diluted earnings were $0.38 a share, against a loss of $0.51 a year ago. The company also raised its full-year revenue growth guidance to 15% to 25%.
On the headline numbers this was a strong quarter. HDFC Sky's market recap cited a consensus revenue estimate of roughly $892 million and an expected adjusted loss of $1.09 a share, which means the company beat the revenue forecast by about 47% and the earnings forecast by about $1.47 a share. US revenue was $780 million and international revenue $533 million, according to the release. Research and development fell 27% to $583 million, which assists the profit line by an amount one might describe as "disciplined".
The company's chief executive, Stéphane Bancel, opened his remarks in the release with the sentence "We delivered 29% revenue growth in the third quarter," which is accurate, and a useful reminder that a number can be both true and the first thing you would put in a press release.
Moderna's 2026 guidance changed in three directions. Revenue growth is now expected at 15% to 25%, replacing a previous forecast of "up to 10%". Research and development spending is expected at about $2.7 billion, down from about $2.9 billion. Year-end cash and investments are projected at $8.1 billion to $8.3 billion, up from $4.7 billion to $5.2 billion.
That last revision is the one a forensic accountant would circle. The release says cash and investments stood at $8.0 billion on September 30, up from $6.9 billion on June 30, and that the figure includes about $2.6 billion of net proceeds from convertible notes with a principal amount of roughly $3.0 billion. Revenue growth helped the balance sheet. A convertible helped it more. A convertible, to be clear, is money that has to be paid back or converted into shares, which is a form of cash in the sense that a mortgage is a form of house.
The Morning Brief
Enjoying this? Get it in your inbox.
The profit also has to be read with its neighbours. Moderna recorded a net loss of $1.963 billion over the first nine months of 2026, per the release, so the third quarter's $162 million improves a year that is still deeply in the red. Cost of sales guidance of about $1.7 billion includes a $0.9 billion litigation settlement charge, and the release also records a litigation payment of $950 million.
None of this is concealed. It is in the filing, which is the traditional place to put things one would prefer not to feature in a headline. The point is that a quarter's profit and a year's loss are both accurate descriptions of the same company, and which one appears in the first sentence is a decision made by the person writing the sentence.
The release gives the commercial story something to stand on. Moderna said the US Food and Drug Administration approved its influenza vaccine, mFLUSIVA, in August, the company's fifth approved product. It also reported Phase 3 melanoma data for intismeran, presented at the European Society for Medical Oncology meeting, showing a hazard ratio of 0.58 for recurrence or death against Keytruda alone, in the company's description. A hazard ratio below one means fewer events, and 0.58 is a large amount below one.
These are the claims that justify the rest of the narrative. A company that sells vaccines for respiratory viruses has a revenue line that depends heavily on seasonal demand and public-health policy. A company that sells a cancer product and a flu product has a story. Investors are being asked to move from the former to the latter, and this quarter is the first evidence that they might.
Moderna has scheduled an Analyst Day for November 12, which is the corporate equivalent of the follow-up meeting where the manager asks how the improvement will be sustained. The questions that matter are not complicated. How much of the guidance revision reflects operations and how much reflects financing? What does a normal year of R&D look like at $2.7 billion? And which of the quarter's good news will recur?
For now, the review comment writes itself. Exceeded expectations on revenue. Beat the street on earnings. Strengthened the balance sheet, partly by borrowing. Recommend a promotion on Thursday, subject to the terms of the notes.
Subscriber Only
Subscribe to The Alignment Times and get every article delivered to your inbox.
Photo by Photographer via Pexels
Miles Bancroft
Staff writer covering financial markets and corporate strategy. Has strong opinions about spreadsheets.
Performance Review Season Claims Another Victim
Apr 5, 2026
AI Company Discovers Enterprises Will Pay More If You Call It 'Enterprise'
Apr 3, 2026